PYLARIFY
Total Payments
$9.4M
Transactions
18,689
Doctors
7,242
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.5M | 6,676 | 3,583 |
| 2023 | $2.1M | 6,870 | 3,813 |
| 2022 | $1.9M | 4,020 | 2,416 |
| 2021 | $1.9M | 1,122 | 629 |
| 2019 | $3,263 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 904 | 55.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 811 | 26.0% |
| Consulting Fee | $698,523 | 169 | 7.4% |
| Food and Beverage | $573,249 | 15,897 | 6.1% |
| Travel and Lodging | $380,665 | 879 | 4.1% |
| Space rental or facility fees (teaching hospital only) | $64,100 | 20 | 0.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,530 | 6 | 0.3% |
| Grant | $5,000 | 1 | 0.1% |
| Education | $136.19 | 2 | 0.0% |
Payments by Type
Research
$5.2M
904 transactions
General
$4.2M
17,785 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | PROGENICS PHARMACEUTICALS, INC. | $702,595 | 0 |
| Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant | Progenics Pharmaceuticals, Inc. | $674,590 | 0 |
| PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | Progenics Pharmaceuticals, Inc. | $655,869 | 0 |
| 2-(3-{1-CARBOXY-5-[(6-18F-FLUORO-PYRIDINE-3-CARBONYL)-AMINO]-PENTYL}-UREIDO)-PENTANEDIOIC ACID (PYL) IN PATIENTS WITH HIGH RISK AND BIOCHEMICALLY RECURRENT PROSTATE CANCER | Progenics Pharmaceuticals, Inc. | $487,600 | 0 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-MGH | Progenics Pharmaceuticals, Inc. | $398,912 | 0 |
| MULTIMODAL PET/MRI MACHINE LEARNING APPROACHES FOR CHARACTERIZATION OF PRIMARY PROSTATE CANCER | Progenics Pharmaceuticals, Inc. | $172,463 | 0 |
| High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy | Progenics Pharmaceuticals, Inc. | $155,388 | 0 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-MSKCC | Progenics Pharmaceuticals, Inc. | $151,800 | 0 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-NCI | Progenics Pharmaceuticals, Inc. | $145,084 | 0 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-MSSKCC | Progenics Pharmaceuticals, Inc. | $123,188 | 0 |
| Phase 3 randomized trial of PSMA PET prior to definitive radiotherapy for intermediate- or high-risk prostate cancer | Progenics Pharmaceuticals, Inc. | $110,538 | 0 |
| PROSTRATE SPECIFIC MEMBRANE ANTIGEN (PSMA) SCAN AND MULTIPARAMETRIC MRI FOR PROSTRASTE BIOPSY DETECTION OF CLINICALLY SIGNIFICANT PROSTRATE CANCER | Progenics Pharmaceuticals, Inc. | $95,409 | 0 |
| THE UTILITY OF PSMA PET IMAGING FOR DETECTING EARLY METASTATIC PROSTATE CANCER IN MEN WITH HIGH GC DECIPHER TEST SCORES A SUB AIM OF THE VANDAAM STUDY MCC NO 18523 | PROGENICS PHARMACEUTICALS, INC. | $94,008 | 0 |
| [1685514-1] - PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) SCAN AND MULTIPARAMETRIC MRI FOR PROSTATE BIOPSY DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER | PROGENICS PHARMACEUTICALS, INC. | $88,786 | 0 |
| Impact of PyL PET/CT on Initial and Subsequent Treatment Strategies of Patients with Prostate Cancer (PROSPYL) | Progenics Pharmaceuticals, Inc. | $82,800 | 0 |
| Phase 3 randomized trial of PSMA PET prior to definitive radiation therapy for intermediate- or high-risk prostate cancer | Progenics Pharmaceuticals, Inc. | $77,000 | 0 |
| THE UTILITY OF PSMA-PET IMAGING FOR DETECTING EARLY METASTATIC PROSTATE CANCER IN MEN WITH HIGH GC DECIPHER TEST SCORES: A SUB-AIM OF THE VANDAAM STUDY (MCC #18523) | Progenics Pharmaceuticals, Inc. | $68,985 | 0 |
| [1685514-1] - PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) SCAN AND MULTIPARAMETRIC MRI FOR PROSTATE BIOPSY DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER | Progenics Pharmaceuticals, Inc. | $68,985 | 0 |
| The utility of PSMA-PET imaging for detecting early metastatic prostate cancer in men with high GC Decipher test scores:A sub-aim of the VANDAAM study (MCC #18523) | Progenics Pharmaceuticals, Inc. | $65,504 | 0 |
| MULTIMODAL PET-MRI MACHINE LEARNING APPROACHES FOR CHARACTERIZATION OF PRIMARY PROSTATE CANCER | PROGENICS PHARMACEUTICALS, INC. | $62,672 | 0 |
Top Doctors Receiving Payments for PYLARIFY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $5.3M | 928 |
| , M.D. PH.D | Diagnostic Radiology | Los Angeles, CA | $349,383 | 244 |
| , MD | Radiation Oncology | Oyster Bay, NY | $278,415 | 224 |
| , M.D., PH.D | Nuclear Radiology | Baltimore, MD | $277,478 | 229 |
| , MD | Nuclear Medicine | Saint Louis, MO | $258,459 | 214 |
| , MD | Medical Oncology | San Diego, CA | $240,963 | 13 |
| , MD | Nuclear Imaging & Therapy | Washington, DC | $202,664 | 159 |
| , M.D | Nuclear Medicine | Los Angeles, CA | $168,177 | 161 |
| Daniel Appelbaum | Nuclear Radiology | Burr Ridge, IL | $150,645 | 98 |
| , D.O | Nuclear Radiology | Port Jefferson Station, NY | $131,662 | 86 |
| , M.D | Urology | Augusta, GA | $107,483 | 77 |
| , MD | Radiation Oncology | Panama City, FL | $88,783 | 41 |
| , M.D | Urology | Bronx, NY | $85,208 | 74 |
| , MD | Urology | Dallas, TX | $83,306 | 64 |
| , M.D | Radiation Oncology | Clarkston, MI | $75,968 | 91 |
| Ashley Ross | Urology | Chicago, IL | $65,803 | 48 |
| , MD | Urology | Chicago, IL | $60,608 | 52 |
| , MD | Urology | San Diego, CA | $57,301 | 32 |
| , M.D | Nuclear Medicine | New York, NY | $45,760 | 33 |
| , M.D | Urology | Syracuse, NY | $37,190 | 30 |
| , MD | Radiation Oncology | Fairfield, OH | $37,093 | 28 |
| , M.D | Radiation Oncology | Nashville, TN | $31,248 | 35 |
| , M.D | Urology | Johns Creek, GA | $30,869 | 35 |
| , MD | Urology | Orange, CA | $30,153 | 28 |
| , M.D | Medical Oncology | Washington, DC | $29,159 | 22 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $9.4M
- Total Doctors 7,242
- Transactions 18,689
About PYLARIFY
PYLARIFY is a drug associated with $9.4M in payments to 7,242 healthcare providers, recorded across 18,689 transactions in the CMS Open Payments database. The primary manufacturer is Progenics Pharmaceuticals, Inc..
Payment data is available from 2019 to 2024. In 2024, $3.5M was paid across 6,676 transactions to 3,583 doctors.
The most common payment nature for PYLARIFY is "Unspecified" ($5.2M, 55.3% of total).
PYLARIFY is associated with 20 research studies, including "PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR" ($702,595).